Dublin, Oct. 23, 2017 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Market" report has been added to Research and Markets' offering.
Liquid biopsy is a minimal invasive medical procedure with the ability to detect presence of molecular cancer biomarkers in the biological fluids. The derived test results help doctors in deciding the further steps in treatment of patient for cancer. The test principally involves the use samples of biological fluids such as blood, urine, serum, and saliva, among others and then enrichment of the samples using different techniques such as Next generation Sequencing (NGS) and Polymerase Chain Reaction (PCR) to detect the mutations known to cause cancer.
The liquid biopsy market is expected to grow at near double digit annual growth rate. Abilities of liquid biopsy such as minimal invasiveness, possibility of continuous monitory of patient's response towards treatment, and monitory of clonal mutations, combined with growing prominence for precision medicine have fueled the growth of liquid biopsy market.
The research study comprises of in-depth analysis of market trends and market size through different approaches. The entire market has been segmented and estimated in five different approaches namely by product & services, by biomarker and technology, by cancer type, by end users, and by geography.
In terms of by products & services the market has been segmented into kits & reagents, platforms & instruments, and services. In terms of by biomarker and technology the market has been segmented into circulating tumor cell (CTC), circulating tumor DNA (ctDNA), and extracellular vesicles (EV). In terms of by cancer type the market has been segmented into lung cancer, breast cancer, colorectal cancer, prostate cancer, and liver cancer. In terms of by end users the market has been tracked through hospital & laboratory, government & academic research centers.
Key Topics Covered:
1 EXECUTIVE SUMMARY 1.1 Introduction 1.2 Market Overview 2 REPORT SCOPE AND METHODOLOGY 3 MARKET DYNAMICS
2.1 Market Overview 2.2 Drivers 2.3 Restraints 2.4 Opportunities 2.5 Industry Analysis - Porter's
4 LIQUID BIOPSY MARKET, BY PRODUCT & SERVICE 4.1 OVERVIEW 4.2 KITS & REAGENTS 4.3 PLATFORMS & INSTRUMENTS 4.4 SERVICES 5 LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER using different technologies such as NGS and PCR microarrays 5.1 OVERVIEW 5.2 CIRCULATING TUMOR CELL (CTC) 5.3 CIRCULATING TUMOR DNA (CTDNA) 5.4 EXTRACELLULAR VESICLES (EVS) 5.5 OTHER BIOMARKERS 6 LIQUID BIOPSY MARKET, BY CANCER TYPE 6.1 OVERVIEW 6.2 LUNG CANCER 6.3 BREAST CANCER 6.4 COLORECTAL CANCER 6.5 PROSTATE CANCER 6.6 LIVER CANCER 6.7 OTHER CANCERS
7 LIQUID BIOPSY MARKET, BY END USER 7.1 OVERVIEW 7.2 HOSPITAL AND LABORATORY 7.3 GOVERNMENT AND ACADEMIC RESEARCH CENTERS
8 COMPETITIVE LANDSCAPE
9 LIQUID BIOPSY MARKET, BY GEOGRAPHY 9.1 OVERVIEW 9.2 NORTH AMERICA 9.3 EUROPE 9.4 ASIA-PACIFIC 9.5 LAMEA
10 COMPANY PROFILES 10.1 Adaptive Biotechnologies 10.2 ANGLE plc 10.3 Biocept Inc. 10.4 Bio-Rad Laboratories Inc. 10.5 CareDx 10.6 Cynvenio Biosystems, Inc. 10.7 Epic Sciences 10.8 F.Hoffmann-La Roche AG 10.9 Genomic Health 10.10 Guardant Health, Inc. 10.11 Illumina, Inc. 10.12 JOHNSON& JOHNSON 10.13 MDxHealth, Inc. 10.14 Menarini Silicon Biosystems, Inc. 10.15 Myriad Genetics, Inc. 10.16 Natera, Inc. 10.17 NeoGenomics Laboratories, Inc. 10.18 QIAGEN 10.19 RainDance Technologies, Inc. 10.20 Sysmex Corporation 10.21 Thermo Fisher Scientific 10.22 Trovagene Inc.
For more information about this report visit https://www.researchandmarkets.com/research/p...uid_biopsy
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: In Vitro Diagnostics
